{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:47:56Z","timestamp":1773769676542,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"am","delay-in-days":334,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.lungcan.2021.05.031","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T04:18:16Z","timestamp":1622175496000},"page":"146-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial"],"prefix":"10.1016","volume":"158","author":[{"given":"Armelle","family":"Lavole","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Mazieres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9642-0493","authenticated-orcid":false,"given":"Sophie","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8103-1954","authenticated-orcid":false,"given":"Solenn","family":"Brosseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lize","family":"Kiakouama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Greillier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelie","family":"Guihot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5907-8131","authenticated-orcid":false,"given":"Baptiste","family":"Abbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0212-8684","authenticated-orcid":false,"given":"Marine","family":"Baron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Makinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Langlais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Morin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Philippe","family":"Spano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Cadranel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lungcan.2021.05.031_bib0005","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/QAD.0000000000000071","article-title":"Malignancies in HIV\/AIDS: from epidemiology to therapeutic challenges","volume":"28","author":"Rubinstein","year":"2014","journal-title":"AIDS"},{"issue":"February 1 (2)","key":"10.1016\/j.lungcan.2021.05.031_bib0010","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jamaoncol.2019.4648","article-title":"Immune status and associated mortality after cancer treatment among individuals with HIV in the antiretroviral therapy era","volume":"6","author":"Calkins","year":"2020","journal-title":"JAMA Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.lungcan.2021.05.031_bib0015","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1634\/theoncologist.2019-IO-S1-s05","article-title":"PD-1\/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions","volume":"24","author":"Xia","year":"2019","journal-title":"Oncologist."},{"issue":"7","key":"10.1016\/j.lungcan.2021.05.031_bib0020","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jtho.2018.03.031","article-title":"Safety and efficacy of PD-1 inhibitors among HIV-positive patients with non-small cell lung cancer","volume":"13","author":"Ostios-Garcia","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2021.05.031_bib0025","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nm.1972","article-title":"HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation","volume":"15","author":"Chomont","year":"2009","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.031_bib0030","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41467-019-08798-7","article-title":"PD-1 blockade potentiates HIV latency reversal ex vivo in CD4(+) T cells from ART-suppressed individuals","volume":"10","author":"Fromentin","year":"2019","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.lungcan.2021.05.031_bib0035","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/nm1482","article-title":"Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction","volume":"12","author":"Trautmann","year":"2006","journal-title":"Nat. Med."},{"issue":"7109","key":"10.1016\/j.lungcan.2021.05.031_bib0040","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.lungcan.2021.05.031_bib0045","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2021.05.031_bib0050","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jamaoncol.2020.0465","article-title":"Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 infection: the phase 2 DURVAST study","volume":"6","author":"Gonzalez-Cao","year":"2020","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2021.05.031_bib0055","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-a phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol."},{"issue":"April 20 (2)","key":"10.1016\/j.lungcan.2021.05.031_bib0060","first-page":"00120","article-title":"Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer","volume":"4","author":"Costantini","year":"2018","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.lungcan.2021.05.031_bib0065","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 or at least 50%: a multicentre, open-label, globall, phase 3, randomized, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"issue":"suppl_11","key":"10.1016\/j.lungcan.2021.05.031_bib0070","doi-asserted-by":"crossref","first-page":"xi33","DOI":"10.1093\/annonc\/mdz451.001","article-title":"Nivolumab plus low-dose ipilimumab as first-line treatment of advanced NSCLC: overall survival analysis of CheckMate 817","volume":"30","author":"Barlesi","year":"2019","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2021.05.031_bib0075","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/annonc\/mdy125","article-title":"Functional immune characterization of HIV-associated non-small-cell lung cancer","volume":"29","author":"Pinato","year":"2018","journal-title":"Ann. Oncol."},{"issue":"October 12 (4)","key":"10.1016\/j.lungcan.2021.05.031_bib0080","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3390\/vaccines7040149","article-title":"Breast cancer cells and PD-1\/PD-L1 blockade upregulate the expression of PD-1, CTLA-4, TIM-3 and LAG-3 immune checkpoints in CD4(+) T cells","volume":"7","author":"Saleh","year":"2019","journal-title":"Vaccines (Basel)."},{"issue":"33","key":"10.1016\/j.lungcan.2021.05.031_bib0085","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make clinical trials more representative: American society of clinical oncology and friends of cancer research joint research statement","volume":"35","author":"Kim","year":"2017","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221004116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221004116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:57:28Z","timestamp":1759237048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500221004116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":17,"alternative-id":["S0169500221004116"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.05.031","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.05.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}